Phenol, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-
| Title | Journal |
|---|---|
| Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. | Chemical research in toxicology 20170515 |
| Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro. | Chemico-biological interactions 20170225 |
| Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. | Chemico-biological interactions 20140205 |
| Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. | Expert opinion on drug metabolism & toxicology 20121101 |
| Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. | Neurourology and urodynamics 20121101 |
| ACP Journal Club. Review: drugs for urgency urinary incontinence improve continence in women. | Annals of internal medicine 20121016 |
| Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. | International urogynecology journal 20121001 |
| Re: The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia. | The Journal of urology 20120901 |
| Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding. | International neurourology journal 20120901 |
| Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. | Drug development and industrial pharmacy 20120801 |
| Solifenacin for overactive bladder: a systematic review and meta-analysis. | International urogynecology journal 20120801 |
| Potentiometric determination of tolterodine in batch and flow injection conditions. | Talanta 20120715 |
| Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. | BJU international 20120701 |
| Comparative adherence to oxybutynin or tolterodine among older patients. | European journal of clinical pharmacology 20120701 |
| Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. | BJU international 20120701 |
| Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. | BJU international 20120701 |
| Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. | Annals of internal medicine 20120619 |
| Lower urinary tract symptoms revisited. | International journal of clinical practice 20120601 |
| Recurrent hyponatremia due to tolterodine. | Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20120601 |
| Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. | British journal of clinical pharmacology 20120501 |
| [Overactive bladder after transurethral resection of prostate treated with electroacupuncture therapy and tolterodine]. | Zhongguo zhen jiu = Chinese acupuncture & moxibustion 20120501 |
| Efficacy and safety of propiverine in children with overactive bladder. | Korean journal of urology 20120401 |
| [Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication]. | Zhongguo zhen jiu = Chinese acupuncture & moxibustion 20120301 |
| Effects of Tamsulosin on Urinary Bladder Function and Neuronal Activity in the Voiding Centers of Rats with Cyclophosphamide-induced Overactive Bladder. | International neurourology journal 20120301 |
| The Relations between Enuresis in Childhood and Nocturnal Polyuria Syndrome in Adult Life. | International neurourology journal 20120301 |
| Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ). | International urogynecology journal 20120201 |
| Therapeutic effect of α-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio. | International journal of clinical practice 20120201 |
| Which anticholinergic drug for overactive bladder symptoms in adults. | The Cochrane database of systematic reviews 20120118 |
| Comparative adherence to oxybutynin or tolterodine among older patients. | European journal of clinical pharmacology 20120101 |
| Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder. | Neurourology and urodynamics 20120101 |
| Antimuscarinic effects on current perception threshold: a prospective placebo control study. | Neurourology and urodynamics 20120101 |
| Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. | The Journal of urology 20120101 |
| Re: The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia. | The Journal of urology 20120101 |
| A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. | Patient preference and adherence 20120101 |
| Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. | Frontiers in pharmacology 20120101 |
| Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. | Journal of medical economics 20120101 |
| IKs protects from ventricular arrhythmia during cardiac ischemia and reperfusion in rabbits by preserving the repolarization reserve. | PloS one 20120101 |
| A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples. | Scientia pharmaceutica 20120101 |
| Neurogenic bladder. | Advances in urology 20120101 |
| Nonselective blocking of the sympathetic nervous system decreases detrusor overactivity in spontaneously hypertensive rats. | International journal of molecular sciences 20120101 |
| Urinary Urgency Medications May Compromise Discrete rather than Global Cognitive Skills. | Dementia and geriatric cognitive disorders extra 20120101 |
| Combination of baclofen and antimuscarinics to reduce voiding difficulty in treating women with overactive bladders. | Clinical and experimental obstetrics & gynecology 20120101 |
| A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. | Drug, healthcare and patient safety 20120101 |
| [The use of tolterodine in patients with recurrent chronic cystitis]. | Urologiia (Moscow, Russia : 1999) 20120101 |
| An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. | British journal of clinical pharmacology 20111201 |
| Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. | Prostate cancer and prostatic diseases 20111201 |
| Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol. | Urology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. | Current urology reports 20111001 |
| Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. | International urogynecology journal 20111001 |
| Risk of serious falls associated with oxybutynin and tolterodine: a population based study. | The Journal of urology 20111001 |
| A healthy bladder: a consensus statement. | International journal of clinical practice 20111001 |
| National-wide data on the treatment of BPH in Korea. | Prostate cancer and prostatic diseases 20110901 |
| Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard. | Urology 20110901 |
| In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats. | Naunyn-Schmiedeberg's archives of pharmacology 20110901 |
| Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. | International journal of clinical practice 20110901 |
| Dissimilar effects of tolterodine on detrusor overactivity in awake rats with chemical cystitis and partial bladder outlet obstruction. | International neurourology journal 20110901 |
| Liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry for the simultaneous determination of dimethoxyaschantin, dimethylliroresinol, dimethylpinoresinol, epimagnolin A, fargesin and magnolin in rat plasma. | Biomedical chromatography : BMC 20110801 |
| α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. | British journal of clinical pharmacology 20110801 |
| Nocturnal enuresis-theoretic background and practical guidelines. | Pediatric nephrology (Berlin, Germany) 20110801 |
| Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. | British journal of clinical pharmacology 20110801 |
| A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. | British journal of clinical pharmacology 20110801 |
| Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. | The journal of obstetrics and gynaecology research 20110801 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| FDA approval signals more 'homework' on the horizon in trials. | Nature medicine 20110707 |
| Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents. | The Journal of pharmacology and experimental therapeutics 20110701 |
| Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? | Journal of the American Geriatrics Society 20110701 |
| Efficacy of tolterodine for medical treatment of intramural ureteral stone with vesical irritability. | Urological research 20110601 |
| Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences. | Drug metabolism and pharmacokinetics 20110601 |
| Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. | BJU international 20110501 |
| Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD. | Bioorganic & medicinal chemistry letters 20110501 |
| Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction. | The journal of obstetrics and gynaecology research 20110501 |
| Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. | Current medical research and opinion 20110501 |
| Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. | Current medical research and opinion 20110501 |
| Application of a liquid chromatographic/tandem mass spectrometric method to a kinetic study of derivative glucosamine in healthy human urine. | Journal of pharmaceutical and biomedical analysis 20110428 |
| Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. | International urogynecology journal 20110401 |
| Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. | International journal of clinical practice 20110401 |
| Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. | World journal of urology 20110401 |
| The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum. | World journal of urology 20110401 |
| The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. | Neurourology and urodynamics 20110401 |
| Highly enantioselective hydrogenation of styrenes directed by 2'-hydroxyl groups. | Organic letters 20110401 |
| [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. | Zhonghua nan ke xue = National journal of andrology 20110401 |
| Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. | Korean journal of urology 20110401 |
| Re: Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. | The Journal of urology 20110401 |
| Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women. | International urogynecology journal 20110301 |
| Evaluation of the effect of tolterodine on pupil diameter and anterior chamber parameters with the Pentacam. | Cutaneous and ocular toxicology 20110301 |
| Validation of the urinary sensation scale (USS). | Neurourology and urodynamics 20110301 |
| Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. | Journal of the American Geriatrics Society 20110301 |
| Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. | BJU international 20110201 |
| Early onset of fesoterodine efficacy in subjects with overactive bladder. | BJU international 20110201 |
| Predictors of catheter-related bladder discomfort in the post-anaesthesia care unit. | Annales francaises d'anesthesie et de reanimation 20110201 |
| Bladder reconstruction using bovine pericardium in a case of enterovesical fistula. | Korean journal of urology 20110201 |
| Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. | Digestive diseases and sciences 20110101 |
| Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. | Neurourology and urodynamics 20110101 |
| [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. | Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20110101 |
| Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. | Postgraduate medicine 20110101 |
| Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function. | Korean journal of urology 20110101 |
| Are antimuscarinic drugs effective against urinary frequency mediated by atropine-resistant contractions? | Journal of pharmacological sciences 20110101 |
| Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. | PloS one 20110101 |
| Nocturnal enuresis. | BMJ clinical evidence 20110101 |
| Possible gabapentin and ketamine interaction causing prolonged central nervous system depression during post-operative recovery following cervical laminoplasty: a case report. | Journal of medical case reports 20110101 |
| Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. | BMC urology 20110101 |
| Management of ureteral calculi and medical expulsive therapy in emergency departments. | Journal of emergencies, trauma, and shock 20110101 |
| Pelvic electrical neuromodulation for the treatment of overactive bladder symptoms. | Advances in urology 20110101 |
| An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. | Advances in urology 20110101 |
| Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. | Advances in urology 20110101 |
| The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. | Advances in urology 20110101 |
| Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. | Therapeutics and clinical risk management 20110101 |
| Overactive bladder: the importance of tailoring treatment to the individual patient. | Journal of multidisciplinary healthcare 20110101 |
| Bladder, bowel, and sexual dysfunction in Parkinson's disease. | Parkinson's disease 20110101 |
| A challenging case of gastric outlet obstruction (Bouveret's syndrome): a case report. | Journal of medical case reports 20110101 |
| Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis. | Neurology research international 20110101 |
| Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study. | BMC geriatrics 20110101 |
| Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study). | Advances in urology 20110101 |
| Spinal versus General Anaesthesia in Postoperative Pain Management during Transurethral Procedures. | ISRN urology 20110101 |
| Automated electrophysiology makes the pace for cardiac ion channel safety screening. | Frontiers in pharmacology 20110101 |
| Tolerance of bladder antispasmodics in children with urinary incontinence: An observational study from North India. | Indian journal of pharmacology 20110101 |
| [Administration of M-cholinoblockers after prostatic surgery]. | Urologiia (Moscow, Russia : 1999) 20110101 |
| Assessment of Association of Increased Heart Rates to Cardiovascular Events among Healthy Subjects in the United States: Analysis of a Primary Care Electronic Medical Records Database. | ISRN cardiology 20110101 |
| Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. | International urogynecology journal 20101201 |
| [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20101201 |
| Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. | Korean journal of urology 20101201 |
| Correlation of male overactive bladder with intravesical prostatic protrusion. | Korean journal of urology 20101201 |
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | Healthcare informatics research 20101201 |
| Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. | BJU international 20101101 |
| Treatment options for parasomnias. | Neurologic clinics 20101101 |
| Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. | International journal of urology : official journal of the Japanese Urological Association 20101101 |
| Correlation between Nocturia and Sleep: A Questionnaire Based Analysis. | Korean journal of urology 20101101 |
| [Analysis of urinary storage symptoms following transurethral resection of the prostate]. | Zhonghua nan ke xue = National journal of andrology 20101101 |
| The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. | World journal of urology 20101001 |
| The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20101001 |
| Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. | Urology 20101001 |
| Prospective open label study of solifenacin for overactive bladder in children. | The Journal of urology 20101001 |
| Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. | Journal of the Formosan Medical Association = Taiwan yi zhi 20101001 |
| New insights into molecular targets for urinary incontinence. | Indian journal of pharmacology 20101001 |
| Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. | International journal of pharmaceutics 20100915 |
| Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. | Drug metabolism and disposition: the biological fate of chemicals 20100901 |
| Stent Position Is More Important than α-Blockers or Anticholinergics for Stent-Related Lower Urinary Tract Symptoms after Ureteroscopic Ureterolithotomy: A Prospective Randomized Study. | Korean journal of urology 20100901 |
| [Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients]. | Zhonghua nan ke xue = National journal of andrology 20100901 |
| The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. | BJU international 20100801 |
| A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. | The Journal of urology 20100801 |
| The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. | BJU international 20100801 |
| Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB. | Nature reviews. Urology 20100801 |
| Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. | The Canadian journal of urology 20100801 |
| Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. | BJU international 20100701 |
| Inhibitory effect of anticholinergics on the contraction of isolated caprine urinary bladder detrusor muscle. | Autonomic & autacoid pharmacology 20100701 |
| Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. | American journal of physiology. Gastrointestinal and liver physiology 20100701 |
| AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. | British journal of pharmacology 20100701 |
| New strategies for medical management of overactive bladder in children. | Current opinion in urology 20100701 |
| Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. | BJU international 20100601 |
| Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. | World journal of urology 20100601 |
| The effects of drug and behavior therapy on urgency and voiding frequency. | International urogynecology journal 20100601 |
| Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. | Urology 20100601 |
| [A drug seeks its disease]. | Lakartidningen 20100601 |
| Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. | Urology 20100501 |
| Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication. | The Journal of urology 20100501 |
| The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. | Yonsei medical journal 20100501 |
| Syndrome of inappropriate antidiuretic hormone associated with tolterodine therapy. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100501 |
| Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence. | Neurourology and urodynamics 20100401 |
| Update in women's health. | Journal of general internal medicine 20100401 |
| Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats. | Urology 20100401 |
| A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden. | Scandinavian journal of urology and nephrology 20100401 |
| Solifenacin: scientific evidence in the treatment of overactive bladder. | Archivos espanoles de urologia 20100401 |
| Mixed incontinence: current evidence and future perspectives. | Neurourology and urodynamics 20100401 |
| Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release. | Neurourology and urodynamics 20100301 |
| Overactive bladder medication adherence when medication is free to patients. | The Journal of urology 20100301 |
| Pediatrics: combining antimuscarinics shows promise for overactive bladder. | Nature reviews. Urology 20100201 |
| Fesoterodine fumarate. | Drugs of today (Barcelona, Spain : 1998) 20100201 |
| Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers. | Drug discoveries & therapeutics 20100201 |
| Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. | Current opinion in urology 20100101 |
| Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats. | Neurourology and urodynamics 20100101 |
| Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. | BJU international 20100101 |
| The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder. | Journal of pharmacological sciences 20100101 |
| Contributors to satisfaction with combined drug and behavioral therapy for overactive bladder in subjects dissatisfied with prior drug treatment. | Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society 20100101 |
| The overlap of interstitial cystitis/painful bladder syndrome and overactive bladder. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20100101 |
| Urodynamic Effects of Propiverine on Detrusor Overactivity and Abdominal Straining during Voiding in Awake Rats with Intravesical Prostaglandin E(2) Instillation. | Korean journal of urology 20100101 |
| Functional role of cannabinoid receptors in urinary bladder. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents. | Quality in primary care 20100101 |
| Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. | PloS one 20100101 |
| Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. | Journal of medical economics 20100101 |
| Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. | BMC urology 20100101 |
| Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. | BMC urology 20100101 |
| Do anticholinergics affect reaction time? A possible impact on the course of rehabilitation. | NeuroRehabilitation 20100101 |
| Management of male urinary incontinence. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| Medical management of overactive bladder. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| Recent advances in management of bladder overactivity. | F1000 medicine reports 20100101 |
| The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. | Advances in urology 20100101 |
| Sacral neuromodulation: Therapy evolution. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| New approaches in the management of multiple sclerosis. | Drug design, development and therapy 20100101 |
| Etiopathogenesis and management of bladder dysfunction in patients with posterior urethral valves. | Indian journal of urology : IJU : journal of the Urological Society of India 20100101 |
| [Overactive bladder in patients with infravesical obstruction caused by prostatic adenoma]. | Urologiia (Moscow, Russia : 1999) 20100101 |
| Challenges in the pharmacotherapy of urogenital disorders. | Frontiers in pharmacology 20100101 |
| Bladder dysfunction in diabetes mellitus. | Frontiers in pharmacology 20100101 |
| Stereoselective Inhibition of the hERG1 Potassium Channel. | Frontiers in pharmacology 20100101 |
| Asymmetric conjugate reductions of coumarins. A new route to tolterodine and related coumarin derivatives. | Organic letters 20091203 |
| Basic mechanisms of urgency: roles and benefits of pharmacotherapy. | World journal of urology 20091201 |
| Fesoterodine for the treatment of overactive bladder. | The Annals of pharmacotherapy 20091201 |
| Treatment of dysautonomia associated with Parkinson's disease. | Parkinsonism & related disorders 20091201 |
| Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. | The American journal of geriatric pharmacotherapy 20091201 |
| Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study. | International urogynecology journal and pelvic floor dysfunction 20091101 |
| [Follow-up at 24 months after treatment of overactive bladder with 0.2 % sodium chondroitin sulfate]. | Aktuelle Urologie 20091101 |
| Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. | Pharmaceutical research 20091101 |
| The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. | Journal of endourology 20091101 |
| [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist]. | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20091101 |
| Editorial comment. | The Journal of urology 20091001 |
| Editorial comment. | The Journal of urology 20091001 |
| Editorial comment. | The Journal of urology 20091001 |
| Double anticholinergic therapy for refractory overactive bladder. | The Journal of urology 20091001 |
| Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. | European urology 20090901 |
| Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. | European urology 20090901 |
| Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. | European urology 20090901 |
| Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20090901 |
| Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. | Current medical research and opinion 20090901 |
| Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. | The Journal of urology 20090901 |
| Tolterodine extended-release for overactive bladder. | Expert opinion on pharmacotherapy 20090901 |
| Simultaneous determination of magnolin and epimagnolin A in rat plasma by liquid chromatography with tandem mass spectrometry: Application to pharmacokinetic study of a purified extract of the dried flower buds of Magnolia fargesii, NDC-052 in rats. | Journal of pharmaceutical and biomedical analysis 20090815 |
| A systematic evaluation of factors associated with nocturia--the population-based FINNO study. | American journal of epidemiology 20090801 |
| Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. | International journal of clinical practice 20090801 |
| Tolterodine extended release is well tolerated in older subjects. | International journal of clinical practice 20090801 |
| Propiverinium picrate. | Acta crystallographica. Section E, Structure reports online 20090801 |
| A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results. | BJU international 20090701 |
| Efficacy and tolerability of fesoterodine in women with overactive bladder. | International urogynecology journal and pelvic floor dysfunction 20090701 |
| [Combination of tolterodine and tamsulosin for benign prostatic hyperplasia]. | Zhonghua nan ke xue = National journal of andrology 20090701 |
| Enantioselective synthesis of (R)-tolterodine via CuH-catalyzed asymmetric conjugate reduction. | The Journal of organic chemistry 20090605 |
| Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. | International journal of pharmaceutics 20090605 |
| Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. | BJU international 20090601 |
| Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. | The Journal of urology 20090601 |
| Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. | International urogynecology journal and pelvic floor dysfunction 20090401 |
| Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090401 |
| Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. | BJU international 20090401 |
| Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. | International journal of clinical practice 20090401 |
| Comparison of the effect of anti-muscarinic agents on bladder activity, urinary ATP level, and autonomic nervous system in rats. | Biomedical research (Tokyo, Japan) 20090401 |
| The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. | Swiss medical weekly 20090307 |
| Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? | European urology 20090301 |
| Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? | European urology 20090301 |
| Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? | European urology 20090301 |
| Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. | The Journal of pharmacology and experimental therapeutics 20090301 |
| Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. | European journal of pharmacology 20090301 |
| In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. | British journal of pharmacology 20090301 |
| Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. | Journal of medical economics 20090301 |
| [Proximal urethra portion perforation during TVT-O in a patient with urethral deviation secondary to previous failed Burch surgery]. | Actas urologicas espanolas 20090301 |
| Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. | European urology 20090201 |
| Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. | European urology 20090201 |
| Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. | European urology 20090201 |
| Re: Claus G. Roehrborn, Steven A. Kaplan, J. Stephen Jones, Joseph T. Wang, Tamara Bavendam, Zhonghong Guan. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009;55:472-81. | European urology 20090201 |
| [Multinational clinical trial in Japan and Korea on detrusitol]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20090201 |
| [In vitro effects of a novel class of nitric oxide donating compounds on isolated human urinary bladder]. | Georgian medical news 20090201 |
| Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? | Current opinion in urology 20090101 |
| Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. | Neurourology and urodynamics 20090101 |
| Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. | Health and quality of life outcomes 20090101 |
| Transdermal oxybutynin. | Drugs 20090101 |
| Bladder urothelial cells from patients with interstitial cystitis have an increased sensitivity to carbachol. | Neurourology and urodynamics 20090101 |
| Ratiometric Ca+2 measurement in human recombinant muscarinic receptor subtypes using the Flexstation scanning fluorometer. | Journal of receptor and signal transduction research 20090101 |
| Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. | Clinical drug investigation 20090101 |
| Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. | Acta obstetricia et gynecologica Scandinavica 20090101 |
| The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. | Clinical interventions in aging 20090101 |
| Clinical pharmacokinetics and pharmacodynamics of solifenacin. | Clinical pharmacokinetics 20090101 |
| A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. | BMC medical research methodology 20090101 |
| The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. | Indian journal of psychiatry 20090101 |
| Use of open-ended Foley catheter to treat profuse urine leakage around suprapubic catheter in a female patient with spina bifida who had undergone closure of urethra and suprapubic cystostomy: a case report. | Cases journal 20090101 |
| The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. | Current medicinal chemistry 20090101 |
| Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena? | Indian pacing and electrophysiology journal 20090101 |
| Male urinary incontinence: prevalence, risk factors, and preventive interventions. | Reviews in urology 20090101 |
| Neuromuscular electrical stimulation and dietary interventions to reduce oxidative stress in a secondary progressive multiple sclerosis patient leads to marked gains in function: a case report. | Cases journal 20090101 |
| Oxybutynin extended release for the management of overactive bladder: a clinical review. | Drug design, development and therapy 20090101 |
| Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. | BMC urology 20090101 |
| Therapeutic options in the treatment of benign prostatic hyperplasia. | Patient preference and adherence 20090101 |
| Sudden elevation of liver enzymes in a 64-year-old patient: a case report. | Cases journal 20090101 |
| Laparoscopic sacrohysteropexy and myomectomy for uterine prolapse: a case report and review of the literature. | Journal of medical case reports 20090101 |
| Ureteral stent discomfort: Etiology and management. | Indian journal of urology : IJU : journal of the Urological Society of India 20090101 |
| Fesoterodine for the treatment of urinary incontinence and overactive bladder. | Therapeutics and clinical risk management 20090101 |
| Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. | Advances in urology 20090101 |
| Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. | PloS one 20090101 |
| Duloxetine for treatment of male sphincteric incontinence following partial conus medullaris infarction after coronary bypass surgery. | Cases journal 20090101 |
| Reverse-phase, high performance liquid chromatographic method for the determination of tolterodine tartrate in routine quality control samples. | PDA journal of pharmaceutical science and technology 20090101 |
| Urodynamics post stroke in patients with urinary incontinence: Is there correlation between bladder type and site of lesion? | Annals of Indian Academy of Neurology 20090101 |
| Rehabilitation challenges in multiple sclerosis. | Annals of Indian Academy of Neurology 20090101 |
| Stability Indicating HPLC Method for the Determination of Chiral Purity of R-(-)-5-[2-aminopropyl]-2-methoxybenzene Sulfonamide. | Indian journal of pharmaceutical sciences 20090101 |
| Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation. | Indian journal of human genetics 20090101 |
| Tolterodine immediate release improves sexual function in women with overactive bladder. | The journal of sexual medicine 20081201 |
| Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. | Journal of cardiovascular pharmacology and therapeutics 20081201 |
| The role of combination medical therapy in benign prostatic hyperplasia. | International journal of impotence research 20081201 |
| Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. | Journal of pediatric urology 20081201 |
| Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. | Current medical research and opinion 20081201 |
| Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. | Obstetrics and gynecology 20081201 |
| Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. | BJU international 20081101 |
| Comparison of fesoterodine and tolterodine in patients with overactive bladder. | BJU international 20081101 |
| Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. | International urogynecology journal and pelvic floor dysfunction 20081101 |
| Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. | International journal of clinical practice 20081101 |
| Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. | International urogynecology journal and pelvic floor dysfunction 20081101 |
| Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. | International journal of clinical practice 20081101 |
| Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. | Urology 20081101 |
| The effects of reformulation: improved therapeutic index. | Current urology reports 20081101 |
| Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial. | Pediatrics 20081101 |
| Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. | International journal of clinical practice 20081101 |
| Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. | European urology 20081001 |
| Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. | European urology 20081001 |
| Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. | European urology 20081001 |
| Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. | International urogynecology journal and pelvic floor dysfunction 20081001 |
| A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. | European urology 20081001 |
| Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. | Clinical therapeutics 20081001 |
| The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. | European urology 20080901 |
| How many drugs for LUTS due to BPH are too many? | The Journal of urology 20080901 |
| Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. | The Journal of urology 20080901 |
| Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. | Urology 20080901 |
| Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. | Clinical interventions in aging 20080901 |
| Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. | Annals of internal medicine 20080805 |
| A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. | Current medical research and opinion 20080801 |
| Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. | Sleep medicine 20080701 |
| Anticholinergic activity of 107 medications commonly used by older adults. | Journal of the American Geriatrics Society 20080701 |
| Impact of fesoterodine on quality of life: pooled data from two randomized trials. | BJU international 20080701 |
| Solifenacin at 3 years: a review of efficacy and safety. | Postgraduate medicine 20080701 |
| In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder. | Naunyn-Schmiedeberg's archives of pharmacology 20080601 |
| Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20080601 |
| In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. | The Journal of pharmacology and experimental therapeutics 20080601 |
| Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. | Drug metabolism and disposition: the biological fate of chemicals 20080601 |
| Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. | Current medical research and opinion 20080601 |
| Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. | International journal of clinical practice 20080601 |
| Hyponatremia associated with tolterodine therapy. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601 |
| Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. | Neuroscience letters 20080502 |
| Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. | International urogynecology journal and pelvic floor dysfunction 20080501 |
| The neurogenic bladder: medical treatment. | Pediatric nephrology (Berlin, Germany) 20080501 |
| Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. | European urology 20080501 |
| Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. | Journal of the American Geriatrics Society 20080501 |
| Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. | The Journal of urology 20080501 |
| Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms. | The Journal of urology 20080501 |
| Tolterodine for the treatment of overactive bladder. | Expert opinion on pharmacotherapy 20080501 |
| Overactive bladder disease: the urge for better therapies. | Journal of managed care pharmacy : JMCP 20080501 |
| Urgency in overactive bladder: translating experimental data into clinical practice. | Drugs of today (Barcelona, Spain : 1998) 20080501 |
| Neurogenic bladder: etiology and assessment. | Pediatric nephrology (Berlin, Germany) 20080401 |
| A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. | International journal of clinical practice 20080401 |
| Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. | Journal of managed care pharmacy : JMCP 20080401 |
| Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. | Journal of pediatric urology 20080401 |
| Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. | Annals of internal medicine 20080318 |
| The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. | BJU international 20080301 |
| A simple validated scale to measure urgency. | The Journal of urology 20080301 |
| Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study. | Pediatric nephrology (Berlin, Germany) 20080201 |
| Thorough QT study with recommended and supratherapeutic doses of tolterodine. | Clinical pharmacology and therapeutics 20080201 |
| Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). | International journal of clinical practice 20080201 |
| A review of solifenacin in the treatment of urinary incontinence. | Therapeutics and clinical risk management 20080201 |
| Tolterodine does not affect memory assessed by passive-avoidance response test in mice. | European journal of pharmacology 20080128 |
| The effects of anticholinergic drugs on attention span and short-term memory skills in children. | Neurourology and urodynamics 20080101 |
| Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. | International journal of clinical practice 20080101 |
| Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice. | International urogynecology journal and pelvic floor dysfunction 20080101 |
| Pharmacological analysis of the interaction of antimuscarinic drugs at M(2) and M(3) muscarinic receptors in vivo using the pithed rat assay. | Naunyn-Schmiedeberg's archives of pharmacology 20080101 |
| [Anticholinergic drugs in overactive bladder]. | Gynecologie, obstetrique & fertilite 20080101 |
| Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101 |
| Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats. | International journal of urology : official journal of the Japanese Urological Association 20080101 |
| Burrowing of urinary bladder wall by the tip of a size 22 Fr silicone foley catheter in an adult male patient with multiple sclerosis and suprapubic cystostomy: should caution be exercised in using a size 22 Fr silicone foley catheter for long-term drainage of neuropathic bladder? | Cases journal 20080101 |
| Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium. | BMC neuroscience 20080101 |
| Practical management of nocturia in urology. | Indian journal of urology : IJU : journal of the Urological Society of India 20080101 |
| Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. | Patient preference and adherence 20080101 |
| A novel metered dose transdermal spray formulation for oxybutynin. | Indian journal of pharmaceutical sciences 20080101 |
| Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder. | European journal of pharmacology 20071222 |
| Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. | World journal of urology 20071201 |
| Does tolterodine extended release affect the bladder electrical perception threshold? A placebo controlled, double-blind study with 4 and 8 mg in healthy volunteers. | The Journal of urology 20071201 |
| Mixed urinary incontinence: continuing to confound? | Current opinion in obstetrics & gynecology 20071201 |
| Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. | European urology 20071101 |
| Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. | European urology 20071101 |
| Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same? | BJOG : an international journal of obstetrics and gynaecology 20071101 |
| Muscarinic receptor antagonists for overactive bladder. | BJU international 20071101 |
| Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. | European journal of pharmacology 20071031 |
| Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. | European urology 20071001 |
| Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. | European urology 20071001 |
| A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. | BJU international 20071001 |
| The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. | BJU international 20070901 |
| Pharmacologic management of overactive bladder. | Clinical interventions in aging 20070901 |
| Enantioselective synthesis of (s)- and (R)-tolterodine by asymmetric hydrogenation of a coumarin derivative obtained by a Heck reaction. | The Journal of organic chemistry 20070803 |
| Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. | European urology 20070801 |
| Age related pathogenesis of nocturia in patients with overactive bladder. | The Journal of urology 20070801 |
| Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. | Current medical research and opinion 20070801 |
| Impact of Medicare changes in pharmacy reimbursement on patient care: two case reports. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070801 |
| Cognitive dysfunction with tolterodine use. | American journal of obstetrics and gynecology 20070801 |
| Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. | The Journal of urology 20070701 |
| The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. | BJU international 20070701 |
| Overactive bladder treatments in early phase clinical trials. | Expert opinion on investigational drugs 20070701 |
| Agents for treatment of overactive bladder: a therapeutic class review. | Proceedings (Baylor University. Medical Center) 20070701 |
| [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH]. | Zhonghua yi xue za zhi 20070619 |
| Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? | BJU international 20070601 |
| Efficacy of combined anticholinergic treatment and behavioral modification as a first line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial. | The Journal of urology 20070601 |
| Update on drugs for overactive bladder syndrome. | Drug and therapeutics bulletin 20070601 |
| A standardised mini pig model for in vivo investigations of anticholinergic effects on bladder function and salivation. | Pharmacological research 20070501 |
| Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. | Geriatrics 20070501 |
| Overactive bladder: recognition requires vigilance for symptoms. | Cleveland Clinic journal of medicine 20070501 |
| Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. | European urology 20070401 |
| Transdermal oxybutynin: sticking to the facts. | European urology 20070401 |
| [How do medications used to treat urinary incontinence affect the cerebral function of the elderly?]. | Der Urologe. Ausg. A 20070401 |
| [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]. | Der Urologe. Ausg. A 20070401 |
| Onset of efficacy of tolterodine extended release in patients with overactive bladder. | Current medical research and opinion 20070401 |
| Comparative evaluation of efficacy of use of tamsulosin and/or tolterodine for medical treatment of distal ureteral stones. | Urology 20070401 |
| Treatment of men with lower urinary tract symptoms and overactive bladder. | JAMA 20070321 |
| Treatment of men with lower urinary tract symptoms and overactive bladder. | JAMA 20070321 |
| Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. | Chinese medical journal 20070305 |
| [Urinary symptoms and urodynamic findings in Parkinson's disease]. | Neurologia (Barcelona, Spain) 20070301 |
| Thorough QT study with recommended and supratherapeutic doses of tolterodine. | Clinical pharmacology and therapeutics 20070301 |
| An enantiospecific HPLC method for the determination of (S)-enantiomer impurities in (R)-tolterodine tartarate. | Die Pharmazie 20070301 |
| Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. | European journal of pharmacology 20070227 |
| Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. | BJU international 20070201 |
| Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. | The Journal of urology 20070201 |
| Is drug therapy for urinary incontinence used optimally in long-term care facilities? | Journal of the American Medical Directors Association 20070201 |
| [Detrusitol and memory impairment]. | Lakartidningen 20070201 |
| Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study. | Contemporary clinical trials 20070101 |
| The responsiveness of the OAB-q among OAB patient subgroups. | Neurourology and urodynamics 20070101 |
| Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. | Neurourology and urodynamics 20070101 |
| Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. | Biological & pharmaceutical bulletin 20070101 |
| Male overactive bladder: the role of urodynamics and anticholinergics. | Current urology reports 20070101 |
| Correlations between the ICIQ-SF score and urodynamic findings. | Neurourology and urodynamics 20070101 |
| Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. | International urology and nephrology 20070101 |
| Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. | Arzneimittel-Forschung 20070101 |
| Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. | Arzneimittel-Forschung 20070101 |
| Identification of the patient with enlarged prostate: diagnosis and guidelines for management. | Osteopathic medicine and primary care 20070101 |
| Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. | Urologia internationalis 20070101 |
| Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. | Scandinavian journal of urology and nephrology 20070101 |
| [Working with urinary incontinence in primary health care: satisfaction, sexuality and therapeutic compliance]. | Archivos espanoles de urologia 20070101 |
| A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis. | Scandinavian journal of urology and nephrology 20070101 |
| Nocturnal enuresis. | BMJ clinical evidence 20070101 |
| Application of evidence-based urology in improving quality of care. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Refractory overactive bladder: Beyond oral anticholinergic therapy. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| A review of urodynamic evaluation in children and its role in the management of boys with posterior urethral valves. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Newer agents for the management of overactive bladder. | American family physician 20061215 |
| Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061201 |
| Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. | Journal of Korean medical science 20061201 |
| [Treatment of overactive bladder with sodium chondroitin sulphate]. | Zentralblatt fur Gynakologie 20061201 |
| Treatment of overactive bladder in the aging population: focus on darifenacin. | Clinical interventions in aging 20061201 |
| Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. | JAMA 20061115 |
| The puzzle of overactive bladder: controversies, inconsistencies, and insights. | International urogynecology journal and pelvic floor dysfunction 20061101 |
| Tolterodine for treatment of overactive bladder. | The Urologic clinics of North America 20061101 |
| Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? | Naunyn-Schmiedeberg's archives of pharmacology 20061101 |
| Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. | The Journal of urology 20061101 |
| In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. | Journal of cardiovascular pharmacology 20061101 |
| Effectiveness of tolterodine in nonneurogenic voiding dysfunction. | Indian pediatrics 20061101 |
| Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. | The Cochrane database of systematic reviews 20061018 |
| [More quality of life again with tolterodine]. | Praxis 20061018 |
| Enantiomeric purity methods for three pharmaceutical compounds by electrokinetic capillary chromatography utilizing highly sulfated-gamma-cyclodextrin as the chiral selector. | Journal of chromatography. A 20060915 |
| Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. | International urogynecology journal and pelvic floor dysfunction 20060901 |
| Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. | Current urology reports 20060901 |
| Solifenacin succinate for the treatment of symptoms of overactive bladder. | Clinical therapeutics 20060901 |
| Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. | European journal of clinical pharmacology 20060801 |
| A meta-analysis comparing trials of antimuscarinic medications funded by industry or not. | BJU international 20060801 |
| Solifenacin significantly improves all symptoms of overactive bladder syndrome. | International journal of clinical practice 20060801 |
| Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. | Urology 20060801 |
| Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. | Urology 20060801 |
| [Oral anticholinergics in overactive bladder]. | Der Urologe. Ausg. A 20060701 |
| [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]. | Der Urologe. Ausg. A 20060701 |
| Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice. | Biological & pharmaceutical bulletin 20060701 |
| Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. | Xenobiotica; the fate of foreign compounds in biological systems 20060701 |
| Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. | BJU international 20060601 |
| Tolterodine. | Nursing times 20060601 |
| Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. | International journal of clinical practice 20060601 |
| Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. | International journal of clinical practice 20060601 |
| Canadian Urological Association guidelines on urinary incontinence. | The Canadian journal of urology 20060601 |
| Transdermal oxybutynin in the treatment of overactive bladder. | Clinical interventions in aging 20060601 |
| [A meta-analysis documenting the optimal tolerance profile of tolterodine]. | Revue medicale suisse 20060510 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. | BJU international 20060501 |
| Probable interaction between tolterodine and warfarin. | Pharmacotherapy 20060501 |
| Case series data to encourage randomized trials of bladder retraining compared to antimuscarinic agents. | The Journal of urology 20060401 |
| The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. | Expert opinion on pharmacotherapy 20060401 |
| Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. | Urology 20060401 |
| The causes and consequences of overactive bladder. | Journal of women's health (2002) 20060401 |
| Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. | British journal of anaesthesia 20060301 |
| Benign prostatic hyperplasia in primary care: what you need to know. | The Journal of urology 20060301 |
| Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. | The Journal of urology 20060301 |
| Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. | The American journal of medicine 20060301 |
| Management of overactive bladder and urge urinary incontinence in the elderly patient. | The American journal of medicine 20060301 |
| The emergence of new drugs for overactive bladder. | Expert opinion on emerging drugs 20060301 |
| Patients with overactive bladders deserve better. | The New Zealand medical journal 20060217 |
| Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. | BJU international 20060201 |
| Muscarinic receptors in the bladder: from basic research to therapeutics. | British journal of pharmacology 20060201 |
| Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. | International journal of urology : official journal of the Japanese Urological Association 20060201 |
| Potent anti-muscarinic activity in a novel series of quinuclidine derivatives. | Bioorganic & medicinal chemistry letters 20060115 |
| Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. | European journal of pharmacology 20060104 |
| Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. | The Journal of pharmacology and experimental therapeutics 20060101 |
| Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70. | European urology 20060101 |
| Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. | The Journal of urology 20060101 |
| Anticholinergic drugs for overactive bladder. | American family physician 20060101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060101 |
| [Comparative assessment of combined therapy of neurogenic hyperactivity of detrusor in patients with Parkinson's disease]. | Urologiia (Moscow, Russia : 1999) 20060101 |
| The latest in treatments for incontinence in women. | Nebraska nurse 20060101 |
| Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. | Neurourology and urodynamics 20060101 |
| Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy. | International urology and nephrology 20060101 |
| [News in the pharmacological treatment of female urinary incontinence]. | Casopis lekaru ceskych 20060101 |
| Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices. | Reviews in urology 20060101 |
| An approach to daytime wetting in children. | Advances in pediatrics 20060101 |
| Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. | International urology and nephrology 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| [Overactive bladder: modulating the effects of antimuscarinic therapy]. | Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20051201 |
| Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. | The Journal of urology 20051201 |
| Clinical observations of the effect of antidiuretic hormone on nocturia in elderly men. | BJU international 20051201 |
| Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. | British journal of clinical pharmacology 20051201 |
| Juvenile pig detrusor: effects of propiverine and three of its metabolites. | European journal of pharmacology 20051107 |
| Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. | The Journal of urology 20051101 |
| Bladder-health diaries: an assessment of 3-day vs 7-day entries. | BJU international 20051101 |
| Solifenacin versus tolterodine--a head-to-head study: finally! But not final? | Current urology reports 20051101 |
| Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. | Expert opinion on pharmacotherapy 20051101 |
| Contemporary treatment options for overactive bladder. | JAAPA : official journal of the American Academy of Physician Assistants 20051101 |
| Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20051101 |
| Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists. | Journal of medicinal chemistry 20051020 |
| Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists. | Bioorganic & medicinal chemistry 20051015 |
| Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. | The Journal of urology 20051001 |
| The efficacy of tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. | Anesthesia and analgesia 20051001 |
| High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050925 |
| Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. | European urology 20050901 |
| Management of nocturnal enuresis in Greek children. | Pediatric nephrology (Berlin, Germany) 20050901 |
| A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. | European urology 20050901 |
| Role of muscarinic receptor antagonists in urgency and nocturia. | BJU international 20050901 |
| Tolterodine-induced hyponatraemia. | Age and ageing 20050901 |
| A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. | The Journal of urology 20050801 |
| Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. | The Journal of urology 20050801 |
| Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. | Journal of clinical pharmacology 20050801 |
| Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. | BJU international 20050801 |
| Which anticholinergic drug for overactive bladder symptoms in adults. | The Cochrane database of systematic reviews 20050720 |
| Studies of drug binding to plasma proteins using a variant of equilibrium dialysis. | Journal of pharmaceutical and biomedical analysis 20050701 |
| Ocular complications of neurological therapy. | European journal of neurology 20050701 |
| Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. | European urology 20050701 |
| Assessment and management of urinary incontinence. | The Nurse practitioner 20050701 |
| Persistence with overactive bladder pharmacotherapy in a Medicaid population. | The American journal of managed care 20050701 |
| Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. | The American journal of managed care 20050701 |
| Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. | The American journal of managed care 20050701 |
| Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. | The American journal of managed care 20050701 |
| Safety and tolerability of tolterodine for the treatment of overactive bladder in adults. | The American journal of managed care 20050701 |
| Mixed incontinence. | The Journal of urology 20050601 |
| Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. | The Journal of urology 20050601 |
| Cholinergic and purinergic responses in isolated human detrusor in relation to age. | The Journal of urology 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. | American journal of obstetrics and gynecology 20050601 |
| Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. | Therapeutics and clinical risk management 20050601 |
| Rhodium-catalyzed asymmetric 1,4-addition of arylboronic acids to coumarins: asymmetric synthesis of (R)-tolterodine. | Organic letters 20050526 |
| Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. | BJU international 20050501 |
| Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. | British journal of clinical pharmacology 20050501 |
| Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. | International journal of urology : official journal of the Japanese Urological Association 20050501 |
| Trospium chloride for the treatment of overactive bladder with urge incontinence. | Clinical therapeutics 20050501 |
| Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine. | Bioorganic & medicinal chemistry letters 20050415 |
| Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. | European journal of pharmacology 20050404 |
| Tolterodine for the treatment of daytime incontinence in children. | The Journal of urology 20050401 |
| Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. | The Journal of urology 20050401 |
| Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20050401 |
| Tolterodine for the treatment of overactive bladder: a review. | Expert opinion on pharmacotherapy 20050401 |
| The responsiveness of the Overactive Bladder Questionnaire (OAB-q). | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20050401 |
| Validation of the urgency perception scale. | BJU international 20050301 |
| Tolterodinium (+)-(2R,3R)-hydrogen tartrate. | Acta crystallographica. Section C, Crystal structure communications 20050301 |
| PHARMAC responds on tolterodine for overactive bladder. | The New Zealand medical journal 20050217 |
| Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. | BJU international 20050201 |
| Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. | Urology 20050201 |
| Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? | Urology 20050201 |
| Overactive bladder: evaluation and management in primary care. | Cleveland Clinic journal of medicine 20050201 |
| Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. | Clinical therapeutics 20050201 |
| [Therapy of bladder weakness]. | Deutsche medizinische Wochenschrift (1946) 20050121 |
| 'Unblinding' in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. | Neurourology and urodynamics 20050101 |
| [Medical therapy of urinary incontinence]. | Der Internist 20050101 |
| [New options in pharmacological treatment of urge urinary incontinence in women]. | Ceska gynekologie 20050101 |
| Contemporary and emerging drug treatments for urinary incontinence in children. | Paediatric drugs 20050101 |
| Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20050101 |
| Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. | International urology and nephrology 20050101 |
| Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions. | BMC pharmacology 20050101 |
| Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations. | PharmacoEconomics 20050101 |
| The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20050101 |
| Overactive bladder in the elderly: a guide to pharmacological management. | Drugs & aging 20050101 |
| Solifenacin in overactive bladder syndrome. | Drugs & aging 20050101 |
| [Less disability in daily activities]. | Krankenpflege Journal 20050101 |
| Nocturnal enuresis in children. A four-year experience in outpatient clinics of pediatric urology. | Folia medica 20050101 |
| Enantioselective [4 + 2] cycloadditions of o-quinone methides: total synthesis of (+)-mimosifoliol and formal synthesis of (+)-tolterodine. | The Journal of organic chemistry 20041224 |
| Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. | European urology 20041201 |
| The patient's perspective: redefining end points. | Urology 20041201 |
| Impact of a health education intervention in overactive bladder patients. | The Canadian journal of urology 20041201 |
| Falls in three patients due to timolol eye drops, tolterodine, and flecainide. | The journals of gerontology. Series A, Biological sciences and medical sciences 20041201 |
| [A clinical study of pelvic floor electrical stimulation in treatment of overactive bladder]. | Zhonghua fu chan ke za zhi 20041201 |
| Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. | Urology 20041101 |
| Hallucinations with tolterodine. | Psychiatric services (Washington, D.C.) 20041101 |
| Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. | World journal of urology 20041001 |
| Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. | BJU international 20041001 |
| Elevating our therapeutic expectations in overactive bladder. | Journal of the American Academy of Nurse Practitioners 20041001 |
| A validated chiral HPLC method for the enantiomeric separation of tolterodine tartarate. | Journal of pharmaceutical and biomedical analysis 20040903 |
| Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. | The Journal of pharmacology and experimental therapeutics 20040901 |
| Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? | The Journal of urology 20040801 |
| Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. | Urology 20040801 |
| [Overactive bladder. New anticholinergic drug controls urinary urge]. | MMW Fortschritte der Medizin 20040708 |
| Signal transduction underlying carbachol-induced contraction of human urinary bladder. | The Journal of pharmacology and experimental therapeutics 20040601 |
| In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. | European journal of pharmacology 20040525 |
| Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. | British journal of clinical pharmacology 20040501 |
| Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. | Clinical pharmacology and therapeutics 20040501 |
| Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder. | BJU international 20040501 |
| [Tolterodine for bladder spasm caused by the indwelling catheter after prostate operation]. | Zhonghua nan ke xue = National journal of andrology 20040501 |
| [Management of neuropathic bladder in multiple sclerosis]. | La Clinica terapeutica 20040501 |
| Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20040501 |
| Cardiac ion channel effects of tolterodine. | The Journal of pharmacology and experimental therapeutics 20040301 |
| Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children. | Urology 20040301 |
| Mixed incontinence. | Urology 20040301 |
| Overactive bladder. Strategies for better recognition and management. | Advance for nurse practitioners 20040301 |
| Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. | Clinical therapeutics 20040301 |
| Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. | The Journal of urology 20040201 |
| Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder. | European urology 20040201 |
| Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. | BJU international 20040201 |
| [Treatment of bladder instability (non-neurogenic hyperactive bladder) in children, with tolterodine]. | Actas urologicas espanolas 20040201 |
| Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. | Life sciences 20040102 |
| Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. | BJU international 20040101 |
| Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen. | Neurourology and urodynamics 20040101 |
| Reliability and validity of King's Health Questionnaire in patients with symptoms of overactive bladder with urge incontinence in Japan. | Neurourology and urodynamics 20040101 |
| Oxybutynin extended-release: a review of its use in the management of overactive bladder. | Drugs 20040101 |
| The handling of urinary incontinence in Danish general practices after distribution of guidelines and voiding diary reimbursement: an observational study. | BMC family practice 20040101 |
| Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. | Drugs 20040101 |
| 30-MINUTES-TUMT. Use of the visual analogue scale to investigate patients' pain perception, different cocktail options and tolerability during 30 minutes' treatment. | Urologia internationalis 20040101 |
| 1-(2-pyrimidinyl)-piperazine, a buspirone metabolite, modulates bladder function in the anesthetized rat. | Neurourology and urodynamics 20040101 |
| Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. | Drug safety 20040101 |
| Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. | The journal of spinal cord medicine 20040101 |
| Trospium chloride in the management of overactive bladder. | Drugs 20040101 |
| A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. | International urogynecology journal and pelvic floor dysfunction 20040101 |
| Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. | PharmacoEconomics 20040101 |
| Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. | Clinical pharmacokinetics 20040101 |
| [Urinary incontinence: anticholinergic treatment]. | Revista de medicina de la Universidad de Navarra 20040101 |
| Oxybutynin extended release and tolterodine immediate release : a health economic comparison. | Clinical drug investigation 20040101 |
| Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria. | Clinical drug investigation 20040101 |
| Transient memory impairment and hallucinations associated with tolterodine use. | The New England journal of medicine 20031204 |
| Overactive bladder: improving the efficacy of anticholinergics by dose escalation. | Current urology reports 20031201 |
| Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. | BJU international 20031201 |
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | British journal of cancer 20031117 |
| Extended-release oxybuytynin and tolterodine treat overactive bladder. | The Journal of family practice 20031101 |
| Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. | BJU international 20031101 |
| Update on overactive bladder: pharmacologic approaches on the horizon. | Current urology reports 20031001 |
| RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. | The Journal of urology 20030901 |
| Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. | BJU international 20030901 |
| Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. | Obstetrics and gynecology 20030901 |
| Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. | Urology 20030801 |
| Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. | The Journal of urology 20030601 |
| Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20030601 |
| [New pharmacological treatment concepts for overactive bladder]. | Der Urologe. Ausg. A 20030601 |
| [Therapy of mixed urinary incontinence]. | Der Urologe. Ausg. A 20030601 |
| Advances in medical management of overactive bladder. | Mayo Clinic proceedings 20030601 |
| Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. | Mayo Clinic proceedings 20030601 |
| Oxybutynin transdermal (Oxytrol) for overactive bladder. | The Medical letter on drugs and therapeutics 20030512 |
| [The medical treatment of overactive bladder]. | Neuro-Chirurgie 20030501 |
| Tolterodine and memory: dry but forgetful. | Archives of neurology 20030501 |
| 25-Hydroxylation of vitamin D3 in primary cultures of pig hepatocytes: evidence for a role of both CYP2D25 and CYP27A1. | Biochemical and biophysical research communications 20030411 |
| [Urinary incontinence--treatment]. | Deutsche medizinische Wochenschrift (1946) 20030404 |
| The use of tolterodine in children after oxybutynin failure. | BJU international 20030301 |
| Clinical study results of tolterodine in patients with overactive bladder. | Expert review of neurotherapeutics 20030301 |
| In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats. | BJU international 20030201 |
| A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. | International urogynecology journal and pelvic floor dysfunction 20030201 |
| Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. | The Journal of urology 20030101 |
| Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. | Neurourology and urodynamics 20030101 |
| Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. | BJU international 20030101 |
| [Spasmex treatment of patients with hyperactive urinary bladder]. | Urologiia (Moscow, Russia : 1999) 20030101 |
| Transdermal oxybutynin: for overactive bladder. | Drugs & aging 20030101 |
| Clinical pharmacokinetics of drugs used to treat urge incontinence. | Clinical pharmacokinetics 20030101 |
| Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. | Clinical drug investigation 20030101 |
| Methodologic shortcomings inherent in a post-hoc analysis. | Current urology reports 20021201 |
| Advances in drug delivery: improved bioavailability and drug effect. | Current urology reports 20021201 |
| Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. | The American journal of managed care 20021201 |
| Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. | The American journal of managed care 20021201 |
| Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20021101 |
| Functional role of central muscarinic receptors for micturition in normal conscious rats. | The Journal of urology 20021101 |
| Different responses to drugs against overactive bladder in detrusor muscle of pig, guinea pig and mouse. | European journal of pharmacology 20021101 |
| Conservative management in neurogenic bladder dysfunction. | Current opinion in urology 20021101 |
| Muscarinic receptor subtypes and management of the overactive bladder. | Urology 20021101 |
| The subtypes of muscarinic receptors for neurogenic bladder contraction in rats. | European journal of pharmacology 20021004 |
| Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. | Current urology reports 20021001 |
| Pharmacologic treatment for detrusor overactivity. | Current urology reports 20021001 |
| The newer antimuscarinic drugs: bladder control with less dry mouth. | Cleveland Clinic journal of medicine 20021001 |
| Characterization of a new muscarinic receptor antagonist PNU-171990 in guinea pig, cat and human smooth muscle. | European journal of pharmacology 20020913 |
| A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. | BJU international 20020901 |
| Does gender or age affect the efficacy and safety of tolterodine? | The Journal of urology 20020901 |
| Gateways to Clinical Trials. | Methods and findings in experimental and clinical pharmacology 20020901 |
| Current pharmacotherapeutic strategies for overactive bladder. | Expert opinion on pharmacotherapy 20020701 |
| Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats. | Urology 20020601 |
| Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. | European urology 20020601 |
| Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. | Journal of the American Geriatrics Society 20020601 |
| The overactive bladder: a nursing perspective. | The American journal of nursing 20020601 |
| Assessment and conservative management of the neuropathic bladder. | Seminars in pediatric surgery 20020501 |
| Tolterodine-associated acute mixed liver injury. | The Annals of pharmacotherapy 20020501 |
| Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. | Journal of the American Geriatrics Society 20020501 |
| Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. | International journal of urology : official journal of the Japanese Urological Association 20020501 |
| Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. | Pharmacology & toxicology 20020501 |
| Achieving bladder control. Treatment in the primary care setting. | Advance for nurse practitioners 20020501 |
| Tolterodine: a safe and effective treatment for older patients with overactive bladder. | Journal of the American Geriatrics Society 20020401 |
| A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). | Clinical therapeutics 20020401 |
| Gateways to Clinical Trials. | Methods and findings in experimental and clinical pharmacology 20020401 |
| Muscarinic receptor antagonist-induced lenticular opacity in rats. | Toxicological sciences : an official journal of the Society of Toxicology 20020301 |
| Pharmacotherapy of the overactive bladder and advances in drug delivery. | Clinical obstetrics and gynecology 20020301 |
| Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. | Urology 20020301 |
| Medication update. | Southern medical journal 20020201 |
| Treatment can lead to a long dry spell. | Business and health 20020101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20020101 |
| Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. | European urology 20020101 |
| Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. | Drugs in R&D 20020101 |
| Comparison of laparoscopic Burch and tension-free vaginal tape in treating stress urinary incontinence in obese patients. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20020101 |
| Overactive bladder patients and role of the pharmacist. | Journal of the American Pharmaceutical Association (Washington,D.C. : 1996) 20020101 |
| New treatment options for overactive bladder and incontinence. | Director (Cincinnati, Ohio) 20020101 |
| Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. | The Cochrane database of systematic reviews 20020101 |
| Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). | Current medical research and opinion 20020101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20020101 |
| Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. | Arzneimittel-Forschung 20020101 |
| Selecting a medical therapy for overactive bladder. | Reviews in urology 20020101 |
| Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence? | The Journal of family practice 20011201 |
| Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. | Clinical therapeutics 20011201 |
| The importance of residues in substrate recognition site 3 for the catalytic function of CYP2D25 (vitamin D 25-hydroxylase). | Biochemical and biophysical research communications 20011109 |
| Medical treatment of overactive bladder. | Mayo Clinic proceedings 20011101 |
| Tolterodine once-daily in treatment of the overactive bladder. | Urology 20011101 |
| Which muscarinic receptor is important in the bladder? | World journal of urology 20011101 |
| Tolterodine: an overview. | World journal of urology 20011101 |
| The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. | Clinical therapeutics 20011101 |
| POEMS (patient-oriented evidence that matters) spark discussion. | The Journal of family practice 20011001 |
| Tolterodine: a clinical review. | Journal of women's health & gender-based medicine 20011001 |
| Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. | Expert opinion on pharmacotherapy 20011001 |
| Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. | European journal of obstetrics, gynecology, and reproductive biology 20010901 |
| [Continence problems after radical prostatectomy: medical treatment]. | Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20010901 |
| Therapeutic opportunities from muscarinic receptor research. | Trends in pharmacological sciences 20010801 |
| Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. | British journal of pharmacology 20010801 |
| Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. | Managed care interface 20010801 |
| Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. | American journal of obstetrics and gynecology 20010701 |
| Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder? | The Journal of family practice 20010701 |
| Clarification--Drug risk in patients with glaucoma. | The Medical letter on drugs and therapeutics 20010611 |
| Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. | Journal of clinical pharmacology 20010601 |
| Tolterodine: a safe and effective treatment for older patients with overactive bladder. | Journal of the American Geriatrics Society 20010601 |
| Urinary incontinence management: new questions from old assumptions. | Journal of the American Geriatrics Society 20010601 |
| [An example of interactions between SSRI preparations and tolterodine?]. | Lakartidningen 20010502 |
| Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. | The Journal of urology 20010501 |
| A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. | Clinical therapeutics 20010501 |
| Clinical experiences with tolterodine. | Life sciences 20010427 |
| Detrol LA and Diropan XL for overactive bladder. | The Medical letter on drugs and therapeutics 20010402 |
| Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry. | British journal of pharmacology 20010401 |
| The overactive bladder in children: a potential future indication for tolterodine. | BJU international 20010401 |
| Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. | Mayo Clinic proceedings 20010401 |
| Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. | World journal of urology 20010401 |
| Use of tolterodine in children with dysfunctional voiding: an initial report. | The Journal of urology 20010301 |
| Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. | Urology 20010301 |
| Overactive bladder: optimizing quality of care. | The American journal of managed care 20010301 |
| Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. | The American journal of managed care 20010301 |
| Food increases the bioavailability of tolterodine but not effective exposure. | Journal of clinical pharmacology 20010301 |
| Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. | British journal of pharmacology 20010201 |
| Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. | Arzneimittel-Forschung 20010201 |
| Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. | Arzneimittel-Forschung 20010201 |
| Practice patterns in the treatment of female urinary incontinence: a postal and internet survey. | Urology 20010101 |
| Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. | Clinical pharmacokinetics 20010101 |
| Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. | Clinical pharmacokinetics 20010101 |
| Tolterodine: a review of its use in the treatment of overactive bladder. | Drugs & aging 20010101 |
| Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. | Drugs & aging 20010101 |
| Failure of tolterodine to treat clozapine-induced nocturnal enuresis. | The Annals of pharmacotherapy 20010101 |
| Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. | Drug safety 20010101 |
| The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. | Journal of autonomic pharmacology 20010101 |
| Implementation of a nursing home urinary incontinence management program with and without tolterodine. | Journal of the American Medical Directors Association 20010101 |
| Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs. | European journal of pharmacology 20000804 |
| Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. | British journal of clinical pharmacology 19991001 |
| Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. | European journal of pharmacology 19980522 |